LUMN vs META
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Lumen Technologies exhibits severe financial distress, anchored by a critical Piotroski F-Score of 2/9 and a negative Price-to-Book ratio of -7.98, which indicates negative shareholders' equity. While the stock has experienced a speculative 1-year price surge of 143.4%, this is decoupled from fundamentals characterized by negative revenue growth (-8.70%) and negative profit margins (-14.02%). The absence of a Graham Number and the bearish technical trend (0/100) further underscore a high-risk profile. Current pricing ($8.69) sits above the analyst target price ($7.67), suggesting the stock is currently overvalued relative to its distressed state.
META exhibits exceptional fundamental health with a Piotroski F-Score of 8/9, indicating strong financial strength across most key metrics. While the current price of $671.34 trades at a significant premium to the Graham Number ($213.08) and the growth-based Intrinsic Value ($541.67), this is justified by a highly attractive Forward P/E of 18.62 and a PEG ratio of 1.10. The company maintains elite profitability margins (82% Gross, 41.3% Operating) and robust revenue growth of 23.8% YoY. Despite bearish insider sentiment and short-term technical weakness, the underlying operational performance and analyst consensus suggest significant upside toward the $855 target.
Compare Another Pair
Related Comparisons
LUMN vs META: Head-to-Head Comparison
This page compares Lumen Technologies, Inc. (LUMN) and Meta Platforms, Inc. (META) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.